Decreased functional response to Toll like receptor ligands in patients with oral cancer

B Paleja1, A Anand, D Chaukar

  • 1Chiplunkar Lab, Advanced Centre for Treatment, Research and Education in Cancer (ACTREC), Tata Memorial Centre, Navi Mumbai, India.

Human Immunology
|May 1, 2013
PubMed

Insights

Toll-like receptor (TLR) signaling is impaired in oral cancer (OC) patients, affecting peripheral blood lymphocytes (PBLs). This dysfunction hinders anti-tumor immunity, suggesting a tumor evasion mechanism.

Area of Science:

  • Immunology
  • Oncology
  • Molecular Biology

Background:

  • Oral cancer (OC) is associated with immune response dysregulation.
  • Toll-like receptors (TLRs) play a crucial role in immune system activation.

Purpose of the Study:

  • To investigate the role of Toll-like receptor (TLR) signaling in peripheral blood lymphocytes (PBLs) of oral cancer patients.
  • To analyze TLR expression and function in various lymphocyte subsets from OC patients.

Main Methods:

  • Flow cytometry was used to analyze TLR expression on lymphocyte subsets.
  • Functional assays assessed TLR-mediated signaling, proliferation, cytokine production (IFN-γ), and activation marker expression (CD25, CD69) upon TLR ligand stimulation.
  • Tumor-directed cytotoxic response was evaluated.

Main Results:

  • Increased TLR expression was observed on unconventional T cells (γδ T cells, NKT cells, CD4(+)CD8(+) T cells) compared to conventional αβ T cells.
  • Peripheral blood lymphocytes (PBLs) from OC patients exhibited impaired TLR signaling, with decreased proliferation and IFN-γ production in response to TLR ligands.
  • TLR ligand stimulation failed to upregulate activation markers or enhance tumor-directed cytotoxic responses in OC PBLs, unlike in healthy individuals.

Conclusions:

  • Impaired TLR signaling on PBLs in oral cancer patients may represent a mechanism by which tumor cells evade immune surveillance.
  • Restoring TLR function could be a potential therapeutic strategy to enhance anti-tumor immunity in oral cancer.